Search Results for 340B

Showing 1 – 4

The Battle Over Neulasta Biosimilars in the US: What's Coming in 2018 By Zachary Brennan - Published 18 January 2018

2016 and 2017 were difficult years for companies trying to win US Food and Drug Administration (FDA) approval for biosimilars of Amgen's blockbuster for treating side effects from chemotherapy.

Categories: News, US, FDA, Regulatory intelligence, Regulatory strategy

Tags: Neulasta, Mylan, Coherus, Amgen, 340B

House E&C Offers Recommendations to Improve 340B Drug Pricing Program By Zachary Brennan - Published 10 January 2018

The House Energy & Commerce (E&C) Committee on Wednesday released an 80-page report outlining issues related to the 340B drug pricing program, which helps reduce the prices of certain drugs for participating hospitals, health centers and other entities that provide care for vulnerable patients, and recommendations to improve the program’s administration.

Categories: News, US, Drugs, Government affairs, Reimbursement

Tags: HRSA, 340B, drug discount, House Energy & Commerce

340B: Health System Execs Push Back on Narrowing of Drug Discount Program By Zachary Brennan - Published 11 October 2017

The House Energy & Commerce's subcommittee on Oversight and Investigations on Wednesday discussed the federal 340B drug discount program, which provides participating hospitals and other medical providers deep discounts on outpatient drugs. 

Categories: News, US, Drugs, Government affairs, Reimbursement

Tags: 340B program, drug discounts, pharmaceutical companies

Despite Industry Opposition, HHS to Fine Drug Companies for Overcharging Hospitals By Zachary Brennan - Published 05 January 2017

The US Department of Health and Human Services (HHS) on Thursday finalized a rule that would fine pharmaceutical companies for overcharging hospitals and clinics for drugs purchased under the 340B drug pricing program.

Categories: News, US, Crisis management, Drugs, Government affairs

Tags: 340B, CMS, drug pricing, Medicaid, PhRMA, BIO, Bayer, Teva